Ignite Creation Date:
2024-05-06 @ 7:48 AM
Last Modification Date:
2024-10-26 @ 11:52 AM
Study NCT ID:
NCT02609659
Status:
COMPLETED
Last Update Posted:
2019-12-10
First Post:
2015-11-18
Brief Title:
OmbitasvirParitaprevirRitonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
An Open-Label Multicenter Study to Evaluate the Efficacy and Safety of OmbitasvirParitaprevirRitonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection GEODE II
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GEODE II
Brief Summary:
This study seeks to assess the safety and efficacy of treatment with ombitasvirparitaprevirritonavir and dasabuvir with low-dose ribavirin in non-cirrhotic genotype 1a GT1a hepatitis C virus infected participants who are treatment-naïve or treatment-experienced with Interferon IFN or Pegylated Interferon pegIFN with or without Ribavirin RBV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None